Jp. Charrier et al., Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis, ELECTROPHOR, 22(9), 2001, pp. 1861-1866
Prostate specific antigen (PSA) is a protease which is characteristic of th
e prostate. it is widely used as a serum marker for the early diagnosis of
prostate cancer (PCa). Nevertheless, for concentrations between 4 and 10 ng
/mL, PSA does not enable PCa to be distinguished from benign diseases, such
as benign prostate hyperplasia (BPH). In sera, the use of a ratio between
free PSA (PSA uncomplexed with protease inhibitor) and total PSA (free PSA
and PSA bound to alpha-1 anti-chymotrypsin) enables the "gray zone" to be r
educed, but an important proportion of patients are still wrongly classed.
Using two-dimensional electrophoresis, we demonstrated using 52 PCa and 40
BPH well-documented clinical cases that BPH sera show a significantly great
er percentage of low-molecular-weight free PSA elements (IwPSA) than PCa se
ra. In our study, the use of a ratio between IwPSA and standard free PSA en
ables the correct diagnosis of 100% of PCa and 82.5% of BPH cases as agains
t when 73.1% and 42.5% respectively were correctly diagnozed using the tota
l PSA and the free/total PSA ratio. This important finding may be related t
o differences in the mechanism secreting PSA from the prostate into the blo
odstream. We have shown how a tissue marker may be turned into a powerful t
umor marker by events probably unrelated to its expression.